NovaScan
NovaScan develops advanced technology for cancer detection and stratification, offering products like MarginScan Skin for dermatologists and nsCanary for real-time biopsy assessment.
Services
NovaScan specializes in developing innovative technology aimed at enhancing cancer detection and stratification. They offer a range of products and solutions designed to improve the accuracy and speed of cancer diagnostics. Their key offerings include MarginScan Skin for dermatologists to efficiently assess skin cancer and nsCanary for real-time biopsy assessments in pancreatic, biliary, and lung applications.
Products
NovaScan's product lineup is spearheaded by MarginScan Skin, an advanced tool for the quick and reliable detection of non-melanoma skin cancer. Another notable product in their pipeline is nsCanary, which is slated for a 2025 release and targets real-time biopsy assessment in critical applications such as pancreatic, biliary, and lung cancers. They are also developing groundbreaking predictive technology to assess cancer aggressiveness and potential for metastasis, as well as an electrical mammogram technology to reduce errors in breast cancer detection.
Partnerships and Collaborations
NovaScan has established a significant partnership with Epredia for the U.S. distribution of MarginScan, enhancing its reach in the medical community. Additionally, they have been recognized through competitive awards for pancreatic cancer research in collaboration with Dr. Paul Grippo. Their active participation in leading medical conferences globally underscores their commitment to advancing research in areas like lung and GI cancers.
Research and Development
NovaScan is heavily invested in research and development to create innovative cancer detection solutions. Their electrical mammogram technology, which aims to reduce false positives and negatives in breast cancer detection, is part of their robust R&D efforts. They have also developed predictive technology that could significantly impact the understanding of cancer aggressiveness and metastasis, further positioning them as a leader in the cancer detection field.
Headquarters
NovaScan is based in Chicago, Illinois. Their headquarters is located at 1623 W Fulton St, anchoring them in a central hub for medical innovation and technology development.